Jazz Pharmaceuticals plc Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation
Jazz Pharmaceuticals plc (JAZZ) reported Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation of $14.28 million for the 6-month period ending 2016-06-30, per its 10-Q filed 2016-08-09.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation · last filed 2016-11-08
- Jazz Pharmaceuticals plc adjustments to additional paid in capital, income tax deficiency from share-based compensation for the quarter ending 2016-06-30 was $1.80M, a 5.21% decline year-over-year.
- Jazz Pharmaceuticals plc adjustments to additional paid in capital, income tax deficiency from share-based compensation for the quarter ending 2016-03-31 was $12.48M, a 15.58% decline year-over-year.
- Jazz Pharmaceuticals plc adjustments to additional paid in capital, income tax deficiency from share-based compensation for the quarter ending 2015-09-30 was -$16.36M, a 342.18% decline year-over-year.
- Jazz Pharmaceuticals plc adjustments to additional paid in capital, income tax deficiency from share-based compensation for the quarter ending 2015-06-30 was $1.90M, a 60.02% increase year-over-year.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation 3 month | Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation 3 month as first filed | Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation 6 month | Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation 9 month | Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation 9 month as first filed |
|---|---|---|---|---|---|
| 2016-06-30 | $1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $14.28M 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | $12.48M 10-Q · filed 2016-05-10 | ||||
| 2015-09-30 | -$16.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | -$14.46M derived: sum of 2 quarters · filed 2016-11-08 | $320.00K 10-Q · filed 2016-11-08 | $25.40M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $1.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $16.68M 10-Q · filed 2016-08-09 | |||
| 2015-03-31 | $14.78M 10-Q · filed 2016-05-10 | ||||
| 2014-09-30 | $6.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $7.94M derived: sum of 2 quarters · filed 2015-11-09 | $17.31M 10-Q · filed 2015-11-09 | ||
| 2014-06-30 | $1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $10.55M 10-Q · filed 2015-08-05 | |||
| 2014-03-31 | $9.36M 10-Q · filed 2015-05-07 | -$9.36M 10-Q · filed 2014-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |